Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Bibliometric Analysis to Improve Combined Treatment Strategies for Glioblastoma in America

Author(s): José Molina-García, David Vázquez, Ernesto Piñón, Alonso Portilla, Martha Lilia Tena-Suck, Angel Lee and Carmen Rubio*

Volume 20, Issue 6, 2024

Published on: 05 January, 2024

Page: [578 - 587] Pages: 10

DOI: 10.2174/0115733947279948231213190721

Price: $65

Abstract

Introduction: Bibliometric analysis quantitatively examines scientific literature to extract insights. This article has conducted such analysis on glioblastoma multiforme (GBM) treatment articles. GBM, a prevalent brain tumor, is typically treated with surgery, radiation, and chemotherapy.

Objectives: The article aimed to bibliometrically analyze articles discussing combined GBM treatment to identify impactful research areas and encourage collaboration.

Materials and Methods: The study encompassed a comprehensive search in the Scopus database, spanning articles published from 1974 to 2022. Inclusion criteria encompassed research conducted in the Americas, both clinical and experimental. A total of 772 articles were collected and categorized based on their primary focus on combined treatment approaches.

Results: Clinical studies constituted 52% of articles, suggesting a slight dominance. The analysis unveiled key research moments, including a 1998 focus shift and a pivotal 2005 study on temozolomide- radiation combination. Top journals, trends, and authors were identified, with the USA leading in contributions.

Discussions: Despite high brain tumor incidence, research distribution discrepancy is concerning. Regional epidemiological studies have been endorsed. The dominance of US and German authors in GBM collaboration has raised equity issues due to budget and GDP disparities limiting Latin American representation.

Conclusion: GBM research in the region is dominated by the USA, while contributions from Latin American countries remain limited. The absence of comprehensive epidemiological studies on GBM in Latin America is concerning, considering the evident impact of the disease in the region. This underscores the urgent need for increased research participation and collaboration to advance the understanding and treatment of GBM across Latin American nations.

Keywords: Bibliometry, glioblastoma, radiotherapy, chemotherapy, temozolomide, cancer.

« Previous Next »
Graphical Abstract

[1]
Luukkonen T. Bibliometrics and evaluation of research performance. Ann Med 1990; 22(3): 145-50.
[http://dx.doi.org/10.3109/07853899009147259] [PMID: 2393549]
[2]
Moed HF. New developments in the use of citation analysis in research evaluation. Arch Immunol Ther Exp 2009; 57(1): 13-8.
[http://dx.doi.org/10.1007/s00005-009-0001-5] [PMID: 19219533]
[3]
Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res 2021; 133: 285-96.
[http://dx.doi.org/10.1016/j.jbusres.2021.04.070]
[4]
Rubio C, Tena M, Rojas DA, Sotelo J, Lee A. Research on brain tumors in Mexico: A bibliometric analysis from Latin America. Am J Histol Cytol 2022; 5: 16.
[5]
Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 2014; 23(10): 1985-96.
[http://dx.doi.org/10.1158/1055-9965.EPI-14-0275] [PMID: 25053711]
[6]
Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: A “state of the science” review. Neuro-oncol 2014; 16(7): 896-913.
[http://dx.doi.org/10.1093/neuonc/nou087] [PMID: 24842956]
[7]
Ellor SV, Pagano-Young TA, Avgeropoulos NG. Glioblastoma: Background, standard treatment paradigms, and supportive care considerations. J Law Med Ethics 2014; 42(2): 171-82.
[http://dx.doi.org/10.1111/jlme.12133] [PMID: 25040381]
[8]
Harter DH, Wilson TA, Karajannis MA. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 2014; 5(1): 64.
[http://dx.doi.org/10.4103/2152-7806.132138] [PMID: 24991467]
[9]
Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann Oncol 2017; 28(7): 1457-72.
[http://dx.doi.org/10.1093/annonc/mdx106] [PMID: 28863449]
[10]
Chuang DF, Lin X. Targeted therapies for the treatment of glioblastoma in adults. Curr Oncol Rep 2019; 21(7): 61.
[http://dx.doi.org/10.1007/s11912-019-0807-1] [PMID: 31102038]
[11]
Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults. JAMA 2023; 329(7): 574-87.
[http://dx.doi.org/10.1001/jama.2023.0023] [PMID: 36809318]
[12]
McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA. Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV. Cancer Med 2020; 9(1): 3-11.
[http://dx.doi.org/10.1002/cam4.2686] [PMID: 31701682]
[13]
Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 2021; 1876(2): 188616.
[http://dx.doi.org/10.1016/j.bbcan.2021.188616] [PMID: 34419533]
[14]
Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neurooncol 2018; 20(12): 1566-72.
[http://dx.doi.org/10.1093/neuonc/noy072] [PMID: 29733389]
[15]
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003.
[http://dx.doi.org/10.1056/NEJMoa043331] [PMID: 15758010]
[16]
Liu A, Jiang B, Song C, et al. Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR‐1236/HER2 signaling pathway. MedComm 2023; 4(3): e282.
[http://dx.doi.org/10.1002/mco2.282] [PMID: 37250146]
[17]
Wang K, Zhang F, Wen C, et al. Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and antiglioblastoma therapeutics. Oncol Res 2021; 29(5): 351-63.
[http://dx.doi.org/10.32604/or.2022.025696] [PMID: 37305160]
[18]
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013; 310(17): 1842-50.
[http://dx.doi.org/10.1001/jama.2013.280319] [PMID: 24193082]
[19]
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther 2015; 152: 63-82.
[http://dx.doi.org/10.1016/j.pharmthera.2015.05.005] [PMID: 25944528]
[20]
McBain C, Lawrie TA, Rogozińska E, Kernohan A, Robinson T, Jefferies S. Treatment options for progression or recurrence of glioblastoma: A network meta-analysis. Cochrane Libr 2021; 2021(5): CD013579.
[http://dx.doi.org/10.1002/14651858.CD013579.pub2] [PMID: 34559423]
[21]
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
[http://dx.doi.org/10.1056/NEJMoa043330] [PMID: 15758009]
[22]
Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry 2021; 92(10): 1103-11.
[http://dx.doi.org/10.1136/jnnp-2020-325334] [PMID: 34162730]
[23]
Akmal M, Hasnain N, Rehan A, et al. Glioblastome multiforme: A bibliometric analysis. World Neurosurg 2020; 136: 270-82.
[http://dx.doi.org/10.1016/j.wneu.2020.01.027] [PMID: 31953095]
[24]
Contreras LE. Epidemiology of brain tumors. Rev Med Clin Las Condes 2017; 28(3): 332-8.
[http://dx.doi.org/10.1016/j.rmclc.2017.05.001]
[25]
Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: A long-term analysis. Tumori 2009; 95(2): 191-7.
[http://dx.doi.org/10.1177/030089160909500210] [PMID: 19579865]
[26]
Sohrabi C, Mathew G, Franchi T, et al. Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training-a review. Int J Surg 2021; 86: 57-63.
[http://dx.doi.org/10.1016/j.ijsu.2020.12.008] [PMID: 33444873]
[27]
Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg 2020; 78: 185-93.
[http://dx.doi.org/10.1016/j.ijsu.2020.04.018] [PMID: 32305533]
[28]
Regalado A. Science in Brazil. Brazilian science: Riding a gusher. Science 2010; 330(6009): 1306-12.
[http://dx.doi.org/10.1126/science.330.6009.1306] [PMID: 21127226]
[29]
Shrank WH, Rogstad TL, Parekh N. Waste in the US Health Care System. JAMA 2019; 322(15): 1501-9.
[http://dx.doi.org/10.1001/jama.2019.13978] [PMID: 31589283]
[30]
Rubio C, Luna R, Ibarra-Velasco M, Lee Á. Epilepsy: A bibliometric analysis (1968–2020) of the Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suarez” in Mexico. Epilepsy Behav 2021; 115: 107676.
[http://dx.doi.org/10.1016/j.yebeh.2020.107676] [PMID: 33360176]
[31]
Rubio C, Luna R, Zenteno M, Bowles B, Lee Á. Dementia research and bibliometrics in Latin America: An example from Mexico. Asian J Psychiatr 2022; 67: 102949.
[http://dx.doi.org/10.1016/j.ajp.2021.102949] [PMID: 34871965]
[32]
Rubio C, Rodríguez-Quintero P, Fleury A, et al. Neurocysticercosis research in Mexico: A bibliometric analysis of the Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Frontiers in Tropical Diseases 2022; 3: 975165.
[http://dx.doi.org/10.3389/fitd.2022.975165]

Rights & Permissions Print Cite
Article Metrics
11
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy